Document is current
Any future updates will be listed below
-
Authors
McGee, Joshua E. https://orcid.org/0000-0003-3327-6209
Kirsch, Jack R. https://orcid.org/0000-0002-6808-7056
Kenney, Devin
Cerbo, Faith https://orcid.org/0009-0005-3931-5303
Chavez, Elizabeth C. https://orcid.org/0000-0003-0252-7140
Shih, Ting-Yu
Douam, Florian
Wong, Wilson W. https://orcid.org/0000-0001-8394-889X
Grinstaff, Mark W. https://orcid.org/0000-0002-5453-3668
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA265713, U01CA265713)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB029483, R01EB031904, T32EB006359, T32EB006359)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK132576)
NSF | BIO | Division of Molecular and Cellular Biosciences (2234657)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (T32AI007309, K22AI144050)
- License Information
-
More Information
Article History
Received: 15 September 2023
Accepted: 4 June 2024
First Online: 8 July 2024
Competing interests
: W.W.W. holds equity in Senti Biosciences, 4Immune Therapeutics and Keylicon Biosciences. A patent has been filed based on the findings of this work (J.E.M., W.W.W., M.W.G. and J.R.K.). J.E.M., M.W.G. and J.R.K. hold equity in Keylicon Biosciences. All other authors have no competing interests.
